TapewireFind a company

person · Reporting owner

Wong Hing C

Disclosed activity across 1 company

Tapewire entity
27519
SEC CIK
0001866258

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
HCW Biologics Inc.HCWB · Entity 8172Director · Chief Executive Officer · 10% ownerJuly 29, 2026July 31, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

HCW Biologics Inc.

Report date July 29, 2026 · Filed July 31, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect125,845 Reported balance After 2026-07-29 transaction · row 1
1 source row

Row 1 · 2026-07-29 · Purchase · Acquired 23,210 · Balance 125,845

F1: The reporting person purchased these shares directly from the issuer in a private placement under a Securities Purchase Agreement dated July 29, 2026 ("SPA"), which purchase is exempt from the registration requirements of Section 5 of the Securities Exchange Act of 1934, as amended, pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D thereunder. Additionally, the reporting person is entitled to receive common warrants exercisable for an aggregate of up to 23,210 shares of common stock. Under the terms of the SPA, issuance of the common warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d). Upon issuance, the common warrants will be exercisable immediately and expire 5.5 years from date of issuance.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person purchased these shares directly from the issuer in a private placement under a Securities Purchase Agreement dated July 29, 2026 ("SPA"), which purchase is exempt from the registration requirements of Section 5 of the Securities Exchange Act of 1934, as amended, pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D thereunder. Additionally, the reporting person is entitled to receive common warrants exercisable for an aggregate of up to 23,210 shares of common stock. Under the terms of the SPA, issuance of the common warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d). Upon issuance, the common warrants will be exercisable immediately and expire 5.5 years from date of issuance.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 29, 2026 Filed Jul 31, 2026 20:10 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 23,210 $2.59 $59,997.85
Disclosure

SEC source: 0001493152-26-035634 · ownership.xml · nonDerivative · entry 1

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,845

F1 · kind: The reporting person purchased these shares directly from the issuer in a private placement under a Securities Purchase Agreement dated July 29, 2026 ("SPA"), which purchase is exempt from the registration requirements of Section 5 of the Securities Exchange Act of 1934, as amended, pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D thereunder. Additionally, the reporting person is entitled to receive common warrants exercisable for an aggregate of up to 23,210 shares of common stock. Under the terms of the SPA, issuance of the common warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d). Upon issuance, the common warrants will be exercisable immediately and expire 5.5 years from date of issuance.

Read SEC document
May 22, 2026 Filed May 27, 2026 23:26 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock Purchase Warrant · Derivative 113,879 $0.00 Strike: $1.28 $0.00
Disclosure

SEC source: 0001493152-26-025478 · ownership.xml · derivative · entry 2

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,110

Underlying: Common Stock · 113,879 shares

Expires 2031-11-22

F1 · kind: The reporting person purchased these shares directly from the issuer in a private placement, which purchase is exempt from Section 16(b) in accordance with Rule 16b-3(d) promulgated under the Securities Exchange Act of 1934, as amended.

Read SEC document
May 22, 2026 Filed May 27, 2026 23:26 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 113,879 $1.41 $160,000.00
Disclosure

SEC source: 0001493152-26-025478 · ownership.xml · nonDerivative · entry 1

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 615,790

F1 · kind: The reporting person purchased these shares directly from the issuer in a private placement, which purchase is exempt from Section 16(b) in accordance with Rule 16b-3(d) promulgated under the Securities Exchange Act of 1934, as amended.

Read SEC document
May 16, 2025 Filed May 20, 2025 20:35 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 8,054 $7.45 $60,002.30
Disclosure

SEC source: 0000950170-25-075259 · ownership.xml · nonDerivative · entry 1

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 501,911

F1 · shares: These shares were issued pursuant to a conversion of Unsecured Convertible Promissory Notes which were issued to six holders through a Company financing of an aggregate principal of $270,000 in one-year Notes. The Notes contained a mandatory conversion provision, which resulted in the Notes converting into shares of common stock at a mandatory conversion price of $7.45 per share as set by the registered offering. The Notes converted after the closing of the Company's registered offering on May 15, 2025. The conversion transaction also included an allocated portion of the 2,174,311 shares of Wugen Inc. common stock held by the Company.

Read SEC document
May 08, 2025 Filed May 9, 2025 21:32 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 92,500 $26.00 $2,405,000.00
Disclosure

SEC source: 0000950170-25-068292 · ownership.xml · nonDerivative · entry 1

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 493,857

F1 · kind: These shares are being issued as a portion of and pursuant to the Company entering into a definitive conversion agreement on May 1, 2025, with a conversion date of May 7, 2025, along with 13 other holders of $6.6 million of the outstanding principal of the Secured Notes to convert the Secured Notes for an aggregate of 253,083 shares of the Company's Common Stock at a conversion price of $26.00 per share (on a post-reverse split basis), issuance of an aggregate of 126,540 warrants each exercisable for one share of Common Stock at an exercise price of $26.00 per share (on a post-reverse split basis), and a portion of the 2,174,311 shares of Wugen Inc. common stock held by the Company.

Read SEC document
May 07, 2025 Filed May 9, 2025 21:32 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock Purchase Warrant · Derivative 46,250 $0.00 Strike: $26.00 $0.00
Disclosure

SEC source: 0000950170-25-068292 · ownership.xml · derivative · entry 2

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,250

Underlying: Common Stock · 46,250 shares

Expires 2030-05-07

F1 · kind: These shares are being issued as a portion of and pursuant to the Company entering into a definitive conversion agreement on May 1, 2025, with a conversion date of May 7, 2025, along with 13 other holders of $6.6 million of the outstanding principal of the Secured Notes to convert the Secured Notes for an aggregate of 253,083 shares of the Company's Common Stock at a conversion price of $26.00 per share (on a post-reverse split basis), issuance of an aggregate of 126,540 warrants each exercisable for one share of Common Stock at an exercise price of $26.00 per share (on a post-reverse split basis), and a portion of the 2,174,311 shares of Wugen Inc. common stock held by the Company.

Read SEC document
February 20, 2024 Filed Feb 22, 2024 19:24 UTC HCW Biologics Inc. HCWB · Entity 8172 GrantCommon Stock 739,288 $1.40 $1,035,003.20
Disclosure

SEC source: 0001209191-24-003787 · doc4.xml · nonDerivative · entry 1

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,054,156

F1 · kind: The reporting person purchased these shares directly from the issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d) promulgated under the Securities Exchange Act of 1934, as amended.

Read SEC document
September 14, 2023 Filed Sep 18, 2023 20:36 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 1,800 $2.08 $3,740.76
Disclosure

SEC source: 0001209191-23-049774 · doc4.xml · nonDerivative · entry 1

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,314,868

F1 · price: The range of prices for the shares of Common Stock is from $2.0536 to $2.1109. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price.

Read SEC document
June 02, 2023 Filed Jun 3, 2023 00:25 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 800 $1.54 $1,228.24
Disclosure

SEC source: 0001209191-23-034098 · doc4.xml · nonDerivative · entry 2

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,313,068

F2 · price: The range of prices for the shares of Common Stock is from $1.5045 to $1.5666. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price.

Read SEC document
June 01, 2023 Filed Jun 3, 2023 00:25 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 800 $1.62 $1,294.24
Disclosure

SEC source: 0001209191-23-034098 · doc4.xml · nonDerivative · entry 1

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,312,268

F1 · price: The range of prices for the shares of Common Stock is from $1.60 to $1.6311. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price.

Read SEC document
May 31, 2023 Filed Jun 1, 2023 21:47 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 2,000 $1.55 $3,092.00
Disclosure

SEC source: 0001209191-23-033397 · doc4.xml · nonDerivative · entry 2

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,311,468

F2 · price: The range of prices for the shares of Common Stock is from $1.5148 to $1.5675. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price.

Read SEC document
May 30, 2023 Filed Jun 1, 2023 21:47 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 3,000 $1.55 $4,658.10
Disclosure

SEC source: 0001209191-23-033397 · doc4.xml · nonDerivative · entry 1

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,309,468

F1 · price: The range of prices for the shares of Common Stock is from $1.4944 to $1.6403. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price.

Read SEC document
September 09, 2022 Filed Sep 12, 2022 19:05 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 6,000 $2.70 $16,200.00
Disclosure

SEC source: 0001209191-22-049469 · doc4.xml · nonDerivative · entry 2

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,306,468

Read SEC document
September 08, 2022 Filed Sep 12, 2022 19:05 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 4,000 $2.67 $10,680.00
Disclosure

SEC source: 0001209191-22-049469 · doc4.xml · nonDerivative · entry 1

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,300,468

Read SEC document
September 07, 2022 Filed Sep 7, 2022 21:45 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 6,000 $2.58 $15,480.00
Disclosure

SEC source: 0001209191-22-049055 · doc4.xml · nonDerivative · entry 2

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,296,468

Read SEC document
September 02, 2022 Filed Sep 7, 2022 21:45 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 4,000 $2.55 $10,200.00
Disclosure

SEC source: 0001209191-22-049055 · doc4.xml · nonDerivative · entry 1

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,290,468

Read SEC document
June 10, 2022 Filed Jun 13, 2022 21:16 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 1,520 $2.19 $3,325.76
Disclosure

SEC source: 0001209191-22-036395 · doc4.xml · nonDerivative · entry 1

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,286,468

F1 · price: The range of prices for the shares of Common Stock is from $2.115 to $2.2301. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price.

Read SEC document
June 09, 2022 Filed Jun 9, 2022 21:59 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 2,000 $2.25 $4,490.00
Disclosure

SEC source: 0001209191-22-035554 · doc4.xml · nonDerivative · entry 2

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,284,948

F1 · price: The range of prices for the shares of Common Stock is from $2.24 to $2.25. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price.

Read SEC document
June 07, 2022 Filed Jun 9, 2022 21:59 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 1,000 $2.31 $2,310.00
Disclosure

SEC source: 0001209191-22-035554 · doc4.xml · nonDerivative · entry 1

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,282,948

Read SEC document
September 08, 2021 Filed Sep 10, 2021 21:44 UTC HCW Biologics Inc. HCWB · Entity 8172 GrantStock Option (Right to Buy) · Derivative 800,000 $0.00 Strike: $4.31 $0.00
Disclosure

SEC source: 0001209191-21-055525 · doc4.xml · derivative · entry 1

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 800,000

Underlying: Common Stock · 800,000 shares

Expires 2031-09-07

F1 · derivative.exercise_date: The option will vest as follows: 20% will vest on September 8, 2022, 20% will vest on September 8, 2023, 25% will vest on September 8, 2024 and 35% will vest on September 8, 2025.

Read SEC document
August 31, 2021 Filed Sep 2, 2021 22:15 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 3,830 $3.93 $15,070.28
Disclosure

SEC source: 0001209191-21-054545 · doc4.xml · nonDerivative · entry 1

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,277,948

F1 · price: The range of prices for the shares of Common Stock is from $3.91 to $3.97. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price.

Read SEC document
August 31, 2021 Filed Oct 7, 2021 23:18 UTC Amendment HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 5,830 $3.94 $22,970.20
Disclosure

SEC source: 0001209191-21-059989 · doc4a.xml · nonDerivative · entry 1

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,281,948

F1 · price: The range of prices for the shares of Common Stock is from $3.91 to $3.97. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price.

Read SEC document
August 30, 2021 Filed Aug 30, 2021 23:41 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 6,000 $3.93 $23,599.80
Disclosure

SEC source: 0001209191-21-053958 · doc4.xml · nonDerivative · entry 3

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,274,118

F3 · price: The range of prices for the shares of Common Stock is from $3.91 to $3.96. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price.

Read SEC document
August 27, 2021 Filed Aug 30, 2021 23:41 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 6,000 $3.77 $22,620.00
Disclosure

SEC source: 0001209191-21-053958 · doc4.xml · nonDerivative · entry 2

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,268,118

F2 · price: The range of prices for the shares of Common Stock is from $3.74 to $3.83. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price.

Read SEC document
August 27, 2021 Filed Oct 7, 2021 23:17 UTC Amendment HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 8,000 $3.76 $30,100.00
Disclosure

SEC source: 0001209191-21-059988 · doc4a.xml · nonDerivative · entry 1

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,270,118

F1 · price: The range of prices for the shares of Common Stock is from $3.74 to $3.83. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price.

Read SEC document
August 26, 2021 Filed Aug 30, 2021 23:41 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 6,500 $3.84 $24,969.75
Disclosure

SEC source: 0001209191-21-053958 · doc4.xml · nonDerivative · entry 1

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,262,118

F1 · price: The range of prices for the shares of Common Stock is from $3.80 to $3.89. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price.

Read SEC document
July 22, 2021 Filed Jul 23, 2021 23:04 UTC HCW Biologics Inc. HCWB · Entity 8172 ConversionSeries C Redeemable Preferred Stock · Derivative 1,071,428 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-048063 · doc4.xml · derivative · entry 7

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,071,428 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: Each share of the Series C Redeemable Convertible Preferred Stock automatically converted into one share of the Issuer's Common Stock, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F3 · shares: Represents shares received upon the conversion of shares of Series C Redeemable Convertible Preferred Stock. All shares were purchased jointly by Hing C. Wong and Bee Yau Huang.

F7 · derivative.exercise_date: Each share of the Series C Redeemable Convertible Preferred Stock automatically converted into one share of the Issuer's Common Stock, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F7 · derivative.expiration_date: Each share of the Series C Redeemable Convertible Preferred Stock automatically converted into one share of the Issuer's Common Stock, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

Read SEC document
July 22, 2021 Filed Jul 23, 2021 23:04 UTC HCW Biologics Inc. HCWB · Entity 8172 ConversionSeries B Redeemable Preferred Stock · Derivative 2,954,285 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-048063 · doc4.xml · derivative · entry 6

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,954,285 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each share of the Series B Redeemable Convertible Preferred Stock automatically converted into one share of the Issuer's Common Stock, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F2 · shares: Represents shares received upon the conversion of shares of Series B Redeemable Convertible Preferred Stock. Includes 1,525,714 shares purchased jointly by Hing C. Wong and Bee Yau Huang.

F6 · derivative.exercise_date: Each share of the Series B Redeemable Convertible Preferred Stock automatically converted into one share of the Issuer's Common Stock, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F6 · derivative.expiration_date: Each share of the Series B Redeemable Convertible Preferred Stock automatically converted into one share of the Issuer's Common Stock, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

Read SEC document
July 22, 2021 Filed Jul 23, 2021 23:04 UTC HCW Biologics Inc. HCWB · Entity 8172 ConversionSeries A Redeemable Preferred Stock · Derivative 6,316,691 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-048063 · doc4.xml · derivative · entry 5

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,316,691 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of the Series A Redeemable Convertible Preferred Stock automatically converted into one share of the Issuer's Common Stock, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F1 · shares: Represents shares received upon the conversion of shares of Series A Redeemable Convertible Preferred Stock. Includes 902,977 shares purchased jointly by Hing C. Wong and Bee Yau Huang.

F5 · derivative.exercise_date: Each share of the Series A Redeemable Convertible Preferred Stock automatically converted into one share of the Issuer's Common Stock, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

F5 · derivative.expiration_date: Each share of the Series A Redeemable Convertible Preferred Stock automatically converted into one share of the Issuer's Common Stock, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

Read SEC document
July 22, 2021 Filed Jul 23, 2021 23:04 UTC HCW Biologics Inc. HCWB · Entity 8172 PurchaseCommon Stock 627,500 $8.00 $5,020,000.00
Disclosure

SEC source: 0001209191-21-048063 · doc4.xml · nonDerivative · entry 4

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,255,618

F3 · shares: Represents shares received upon the conversion of shares of Series C Redeemable Convertible Preferred Stock. All shares were purchased jointly by Hing C. Wong and Bee Yau Huang.

F4 · shares: Represents shares of Common Stock purchased in connection with the Issuer's initial public offering for consideration of $8.00 per share.

Read SEC document
July 22, 2021 Filed Jul 23, 2021 23:04 UTC HCW Biologics Inc. HCWB · Entity 8172 ConversionCommon Stock 1,071,428 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-048063 · doc4.xml · nonDerivative · entry 3

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,628,118

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · shares: Represents shares received upon the conversion of shares of Series C Redeemable Convertible Preferred Stock. All shares were purchased jointly by Hing C. Wong and Bee Yau Huang.

Read SEC document
July 22, 2021 Filed Jul 23, 2021 23:04 UTC HCW Biologics Inc. HCWB · Entity 8172 ConversionCommon Stock 2,954,285 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-048063 · doc4.xml · nonDerivative · entry 2

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,556,690

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: Represents shares received upon the conversion of shares of Series B Redeemable Convertible Preferred Stock. Includes 1,525,714 shares purchased jointly by Hing C. Wong and Bee Yau Huang.

Read SEC document
July 22, 2021 Filed Jul 23, 2021 23:04 UTC HCW Biologics Inc. HCWB · Entity 8172 ConversionCommon Stock 6,316,691 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-048063 · doc4.xml · nonDerivative · entry 1

Wong Hing C · CIK 0001866258 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,602,405

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares received upon the conversion of shares of Series A Redeemable Convertible Preferred Stock. Includes 902,977 shares purchased jointly by Hing C. Wong and Bee Yau Huang.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.